Mason Street Advisors LLC grew its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 71.9% in the first quarter, HoldingsChannel.com reports. The firm owned 15,490 shares of the health services provider’s stock after buying an additional 6,478 shares during the period. Mason Street Advisors LLC’s holdings in Amedisys were worth $1,909,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of AMED. JPMorgan Chase & Co. boosted its stake in Amedisys by 14.6% in the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock valued at $116,731,000 after acquiring an additional 118,936 shares during the period. Vanguard Group Inc boosted its stake in Amedisys by 14.3% in the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after acquiring an additional 415,060 shares during the period. Meeder Asset Management Inc. boosted its stake in Amedisys by 107.4% in the fourth quarter. Meeder Asset Management Inc. now owns 477 shares of the health services provider’s stock valued at $56,000 after acquiring an additional 247 shares during the period. Bank of Montreal Can boosted its stake in Amedisys by 2.4% in the fourth quarter. Bank of Montreal Can now owns 21,048 shares of the health services provider’s stock valued at $2,464,000 after acquiring an additional 487 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in Amedisys by 146.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 49,306 shares of the health services provider’s stock valued at $5,774,000 after acquiring an additional 29,262 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.
A number of brokerages have commented on AMED. BidaskClub downgraded Amedisys from a “hold” rating to a “sell” rating in a research note on Friday, May 17th. ValuEngine downgraded Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $151.00 target price for the company in a research note on Thursday, February 7th. Craig Hallum decreased their target price on Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a research note on Friday, March 1st. They noted that the move was a valuation call. Finally, Raymond James upgraded Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 target price for the company in a research note on Thursday, May 2nd. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $125.90.
Shares of NASDAQ AMED opened at $110.07 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91. The company has a market cap of $3.53 billion, a PE ratio of 30.32, a price-to-earnings-growth ratio of 1.39 and a beta of 1.33. Amedisys Inc has a 12-month low of $73.50 and a 12-month high of $140.91.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.89 by $0.22. The business had revenue of $467.34 million during the quarter, compared to the consensus estimate of $460.83 million. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The business’s revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.79 earnings per share. On average, analysts predict that Amedisys Inc will post 4.08 earnings per share for the current year.
In other news, insider David B. Pearce sold 4,370 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $120.01, for a total transaction of $524,443.70. Following the completion of the transaction, the insider now directly owns 13,129 shares in the company, valued at $1,575,611.29. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Christopher Gerard sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $118.96, for a total value of $297,400.00. Following the transaction, the chief operating officer now owns 25,731 shares of the company’s stock, valued at $3,060,959.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,281 shares of company stock valued at $2,710,043. Insiders own 2.90% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Recommended Story: CD Ladder
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.